|1.||Hashimoto, Kenji: 1 article (01/2015)|
|2.||Hosford, David A: 1 article (05/2013)|
|3.||Segreti, Anthony C: 1 article (05/2013)|
|4.||Duan, Naihua: 1 article (05/2013)|
|5.||Beaver, Jessica S: 1 article (05/2013)|
|6.||Lieberman, Jeffrey A: 1 article (05/2013)|
|7.||Seoane, Frances: 1 article (05/2013)|
|8.||Girgis, Ragy R: 1 article (05/2013)|
|9.||Dunbar, Geoffrey: 1 article (05/2013)|
|10.||Papke, R L: 1 article (10/2009)|
|1.||Schizophrenia (Dementia Praecox)
10/01/2009 - "The transgenic th(tk-)/th(tk-) mouse model that reflects many of the developmental, anatomical, and multi-transmitter biochemical aspects of schizophrenia was used to assess the antipsychotic effects of TC-5619. "
05/01/2013 - "This exploratory trial was conducted to test the effects of an alpha7 nicotinic receptor partial agonist, TC-5619, on cognitive dysfunction and negative symptoms in subjects with schizophrenia. "
05/01/2013 - "These results support the potential benefits of TC-5619 and alpha7 nicotinic receptor partial agonists for cognitive dysfunction and negative symptoms in schizophrenia."
10/01/2009 - "These results suggest that alpha7-selective agonists such as TC-5619, either alone or in combination with antipsychotics, could offer a new approach to treating the constellation of symptoms associated with schizophrenia, including cognitive dysfunction."
10/01/2009 - "TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia."
|1.||Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
|2.||Risperidone (Risperdal Consta)
|3.||Antipsychotic Agents (Antipsychotics)
|4.||1- (5- chloro- 2,4- dimethoxyphenyl)- 3- (5- methylisoxazol- 3- yl)urea